- Home
- SGLY vs LIPO Comparison
SGLY vs LIPO Comparison
Compare SGLY & LIPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGLY
- LIPO
- Stock Information
- Founded
- SGLY 2001
- LIPO 2005
- Country
- SGLY United States
- LIPO United States
- Employees
- SGLY N/A
- LIPO N/A
- Industry
- SGLY
- LIPO Biotechnology: Pharmaceutical Preparations
- Sector
- SGLY
- LIPO Health Care
- Exchange
- SGLY Nasdaq
- LIPO Nasdaq
- Market Cap
- SGLY 3.0M
- LIPO 3.1M
- IPO Year
- SGLY 2008
- LIPO 2022
- Fundamental
- Price
- SGLY $0.71
- LIPO $2.65
- Analyst Decision
- SGLY
- LIPO
- Analyst Count
- SGLY 0
- LIPO 0
- Target Price
- SGLY N/A
- LIPO N/A
- AVG Volume (30 Days)
- SGLY 537.0K
- LIPO 177.4K
- Earning Date
- SGLY 05-26-2025
- LIPO 05-08-2025
- Dividend Yield
- SGLY N/A
- LIPO N/A
- EPS Growth
- SGLY N/A
- LIPO N/A
- EPS
- SGLY N/A
- LIPO N/A
- Revenue
- SGLY $2,255,541.00
- LIPO $536,357.00
- Revenue This Year
- SGLY N/A
- LIPO N/A
- Revenue Next Year
- SGLY N/A
- LIPO N/A
- P/E Ratio
- SGLY N/A
- LIPO N/A
- Revenue Growth
- SGLY N/A
- LIPO 19.29
- 52 Week Low
- SGLY $0.54
- LIPO $1.97
- 52 Week High
- SGLY $7.65
- LIPO $12.00
- Technical
- Relative Strength Index (RSI)
- SGLY 47.25
- LIPO 57.23
- Support Level
- SGLY $0.65
- LIPO $2.25
- Resistance Level
- SGLY $0.68
- LIPO $2.44
- Average True Range (ATR)
- SGLY 0.10
- LIPO 0.22
- MACD
- SGLY 0.01
- LIPO 0.04
- Stochastic Oscillator
- SGLY 56.00
- LIPO 88.39
About SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About LIPO Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.